||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 524 active entries
Nobels Alle 10
Phone: +46 8 524 88620
Fax: + 46 8 524 86234
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Axcentua Pharmaceuticals is pioneering a unique strategy, crystal engineering, for accelerated development of novel therapeutics to the clinic. Preclinical studies have shown that the multi-targeted isoflavone, genistein, sensitize tumor cells to chemotherapy and inhibit metastatic spread of several human cancers. Our lead compound, AXP 107-11 is a crystal re-engineered new solid form of genistein. AXP107-11 has superior dissolution rate and solubility profiles, translating into markedly improved oral bioavailability of AXP107-11, compared to the parent from of genistein.
AXP107-11 was developed from bench to clinic in only 2 years and is currently in phase Ib/IIa clinical trials for pancreatic cancer. IP protection of the crystalline form, the crystallization process, composition of matter, and therapeutic use of AXP107-11 is secured through a recent US patent and a pending PCT. Pipeline expansion through novel formulations of AXP107-11 as well as crystal re-engineering of backup candidates is ongoing..
Last update of this entry: July 12, 2011